Medicine company – Diazon http://diazon.net/ Sat, 08 Jan 2022 20:48:43 +0000 en-US hourly 1 https://wordpress.org/?v=5.8 https://diazon.net/wp-content/uploads/2021/11/icon-120x120.jpg Medicine company – Diazon http://diazon.net/ 32 32 Perth-based regenerative medicine company Orthocell created the procedure, known as Ortho-ATI. https://diazon.net/perth-based-regenerative-medicine-company-orthocell-created-the-procedure-known-as-ortho-ati/ Fri, 10 Dec 2021 11:37:01 +0000 https://diazon.net/perth-based-regenerative-medicine-company-orthocell-created-the-procedure-known-as-ortho-ati/ Perth doctors have created a non-invasive, non-surgical solution to help heal chronic tendon injuries. Perth-based regenerative medicine company Orthocell created the procedure, known as Ortho-ATI. First, it is a small tendon biopsy taken from a healthy area and transferred to a laboratory. Doctors in Perth have created a non-invasive, non-surgical solution to chronic tendon injuries. […]]]>
Perth doctors have created a non-invasive, non-surgical solution to help heal chronic tendon injuries.

Perth-based regenerative medicine company Orthocell created the procedure, known as Ortho-ATI.

First, it is a small tendon biopsy taken from a healthy area and transferred to a laboratory.

Doctors in Perth have created a non-invasive, non-surgical solution to chronic tendon injuries. (9News)

There, the tendon’s stem cells are nourished, growing from thousands of cells to millions.

They are then injected into the injury site, allowing new, healthy tendons to rebuild.

“It’s a minimally invasive approach to healing chronic tendon injuries,” said Orthocell CEO Paul Anderson.

Perth-based regenerative <a class=medicine company called Ortho Cell created the procedure, known as OrthoAti. “/>
Perth-based regenerative medicine company called Ortho Cell created the procedure, known as OrthoAti. (9News)

The cells can be stored in the laboratory for up to 20 years and used for future injuries.

Currently, the treatment is only available to patients in clinical trials and is pending approval by the Therapeutic Goods Administration.

West Coast Eagles player Mark LeCras is one of the patients who received the treatment.

West Coast Eagles player Mark LeCras is one of the patients who received the treatment.
West Coast Eagles player Mark LeCras is one of the patients who received the treatment. (9News)

The AFL star nearly lost his career after a nasty knee tendon injury that plagued him for 12 months.

“We’ve tried a few different therapies to try and fix it, but we haven’t really done it,” LeCras said. “It completely healed me.”

He has since played eight more seasons which even included a Premiership victory.


Source link

]]>
Regenerative Medicine Company Vascudyne Closes $ 10 Million Series A Funding https://diazon.net/regenerative-medicine-company-vascudyne-closes-10-million-series-a-funding/ Thu, 02 Dec 2021 14:23:00 +0000 https://diazon.net/regenerative-medicine-company-vascudyne-closes-10-million-series-a-funding/ Stillwater, MN – News Direct – Vascudyne, Inc. The investment will support expanded clinical trials of TRUE Graft, establish a commercial GMP manufacturing facility, and further develop TRUE Tissue platform technology for additional products. Vascudyne, Inc., a biotechnology pioneer in regenerative medicine, today announced that it has raised $ 10 million in Series A cash […]]]>

Stillwater, MN – News Direct – Vascudyne, Inc.

The investment will support expanded clinical trials of TRUE Graft, establish a commercial GMP manufacturing facility, and further develop TRUE Tissue platform technology for additional products.

Vascudyne, Inc., a biotechnology pioneer in regenerative medicine, today announced that it has raised $ 10 million in Series A cash through a global group of investors.

In July, Vascudyne also announced the success first human use of TRUE ™ Graft for access to hemodialysis in patients with end stage renal disease. The early product developments and preclinical studies of Vascudyne were funded by angel investors. Since its incorporation, Vascudyne has transferred regenerative technology, vertically integrated manufacturing and launched the first human clinical trial of TRUE Graft.

Vascudyne TRUE to Nature ™ biomaterials are unique and 100% natural. While other regenerative medicine cardiovascular devices contain scaffolds made from synthetic polymers that slowly break down in the body and can lead to an unwanted immune response, the TRUE ™ fabric the technology is 100% organic: nothing synthetic or artificial is ever used in the manufacturing process.

“We are delighted that investors are sharing our passion to bring our TRUE Tissue platform technology to patients around the world,” said Rick Murphy, vice president of operations and general manager of Vascudyne. “We are developing our BPF manufacturing facility to support the expansion of the clinical safety study of our TRUE Graft for access to hemodialysis and to accelerate the clinical use of new products that are currently under development for more. multiple cardiovascular applications. “

“The closing of the Serie A round is a very exciting step for Vascudyne,” said Kem Schankereli, CEO of Vascudyne. “We are building momentum and leading the way so that we can deliver our TRUE tissue regeneration material technology to patients in need. Series A funding provides the support needed to grow the organization so that we can continue our clinical trials, expand our operations, and translate additional products using our TRUE technology platform, from preclinical to clinical trials. . “

Vascudyne authorized its proprietary TRUE Tissue technology developed by world leader in tissue engineering Robert Tranquillo, PhD, Distinguished Professor at McKnight University, and his colleagues at the University of Minnesota in 2017.

TRUE Graft is not available for commercial sale.

Regenerative <a class=Medicine Company Vascudyne Closes $ 10 Million Series A Funding” src=”https://s.yimg.com/ny/api/res/1.2/QyIpr_WOu4vQU7IgHhLMSA–/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY0Mg–/https://s.yimg.com/uu/api/res/1.2/JxzoSatEuvCdWmuBDTtVWw–~B/aD00Mjg7dz02NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/news_direct/551594b700d44b33d156ecde3a750a82″/>

Regenerative Medicine Company Vascudyne Closes $ 10 Million Series A Funding

About Vascudyne

Based in the heart of Medical Alley, Minnesota, Vascudyne’s mission is to improve patient care with regenerative biomaterials inspired by nature. Vascudyne, a privately held company founded in 2014, uses TRUE ™ Tissue technology to develop TRUE to Nature ™ biomaterials for soft tissue repair and replacement. For more information, please visit https://www.vascudyne.com/.

About TRUE Tissue Technology

TRUE ™ Tissue is developed from cells isolated from donor tissue and is 100% organic. There are no synthetic or chemical fixation materials used, and the implanted tissues are completely cell-derived and acellular. The TRUE Tissue technology can be easily shaped into tubes, sheets and other geometries, making it suitable for many soft tissue applications, is mechanically comparable to native tissue, and is a ready-to-use allograft.

Forward-looking statements

This announcement contains forward-looking statements. Such statements may include, but are not limited to, statements identified by words such as “plans”, “may”, “will”, “could”, “should”, “should”, “believe”, “s ‘expects to’, ‘plans’, ‘estimates’, ‘intentions’, ‘plans’, ‘potential’ or similar expressions. These statements relate to future events or to Vascudyne’s clinical development programs, reflect the current beliefs and expectations of management, and involve known and unknown risks, uncertainties and other factors that may cause results, performance or significantly different actual achievements of Vascudyne. Vascudyne assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future presentations or otherwise, except as required by applicable law.

Contact details

Vascudyne

Sandy Williams, Marketing Director

+1 952-412-5975

swilliams@vascudyne.com

Company Website

https://vascudyne.com/

See the source version on newsdirect.com: https://newsdirect.com/news/regenerative-medicine-company-vascudyne-closes-10-million-series-a-financing-526027886


Source link

]]>
Next Generation Precision Medicine Company Allorion Therapeutics Completes Series A Funding Round https://diazon.net/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round/ Wed, 24 Nov 2021 08:00:00 +0000 https://diazon.net/next-generation-precision-medicine-company-allorion-therapeutics-completes-series-a-funding-round/ BOSTON, November 24, 2021 / PRNewswire / – Allorion Therapeutics, a company specializing in next-generation precision medicine for oncology and autoimmune diseases, today announced the completion of $ 40 million Series A financing. This funding round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital and Elikon Venture. Existing […]]]>

BOSTON, November 24, 2021 / PRNewswire / – Allorion Therapeutics, a company specializing in next-generation precision medicine for oncology and autoimmune diseases, today announced the completion of $ 40 million Series A financing. This funding round is led by Qiming Venture Partners and participated by IDG Capital, Octagon Capital, Firstred Capital and Elikon Venture. Existing investors – TF Capital and Med-Fine Capital – continued to support this round.

The product will be used to support Allorion’s preclinical projects, IND studies and IND applications of two drug candidates in China and United States. Allorion will also increase its investment in its platform technologies in the systematic screening of allosteric inhibitors and synthetic lethality targets with corresponding tool compounds and strengthen the clinical and commercial development teams.

Allorion’s Drug Discovery Engine integrates technological advances in protein structure, big data, machine learning and gene editing to systematically discover and develop highly selective small molecules, including covalent and allosteric inhibitors well validated targets. Allorion has also built a unique synthetic lethality screening platform to expand the reach of targeted therapies for cancer patients, thus laying a solid foundation for the long-term success of the company. Allorion strives to select targets and execute projects and meets high standards in drug discovery and data quality to achieve international recognition and collaboration.

Peter Ding, Founder and CEO of Allorion Therapeutics, said: “On last year, Allorion developed R&D capabilities in Boston and Canton and formed a strong management and R&D team. Several projects have reached their milestones. The completion of this round table shows the recognition by investors of the progress and support for the long-term strategy of the company on highly innovative platforms for the discovery of best or first-in-class drugs. We thank all investors for their trust and support. We will continue our efforts to promote innovative small molecule drugs in clinical research, thereby meeting unmet clinical needs. Allorion will leverage cutting-edge technologies and strive to make precision medicine more precise and accessible to more patients. “

Chen Kan, Director of Qiming Venture Partners, said, “There are huge unmet medical needs for autoimmune diseases and cancer treatment around the world. Based on data mining and a deep understanding of disease biology, Allorion is focused on the early discovery and development of precision drugs. We have confidence in the strong R&D capabilities of the team. We hope to help Allorion become a globally recognized company and improve the quality of life for patients.

About Qiming Venture Partners

Founded in 2006, Qiming Venture Partners is a leader China venture capital firm with offices in Shanghai, Beijing, Suzhou, Hong Kong, Seattle, Boston and the San Francisco Bay Area. Currently, Qiming Venture Partners manages ten american dollars funds and six RMB funds with $ 6.2 billion outstanding under raised capital. Since its inception, Qiming Venture Partners has invested in outstanding TMT and healthcare companies in start-up and growth stages. Since its inception, Qiming Venture Partners has supported more than 430 innovative and fast growing companies. Over 170 companies are already listed on the NYSE, NASDAQ, HKEx, Gretai Securities Market, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or have successfully exited through mergers and acquisitions and other means . There are also over 40 portfolio companies that have achieved unicorn status.

About TF Capital

TF Capital focuses on investing in the life sciences sector, investing primarily in high potential start-ups. Through strategic investments in various key areas and good partnerships, TF Capital hopes to seize opportunities in the growing Chinese life sciences market. Our investment team has extensive industry experience and resources to assist our portfolio companies.

SOURCE Allorion Therapeutics


Source link

]]>
Perrigo buys European drug company for around $ 2 billion https://diazon.net/perrigo-buys-european-drug-company-for-around-2-billion/ https://diazon.net/perrigo-buys-european-drug-company-for-around-2-billion/#respond Wed, 08 Sep 2021 07:00:00 +0000 https://diazon.net/perrigo-buys-european-drug-company-for-around-2-billion/ GRAND RAPIDS, Mich. (WOOD) – West Michigan self-care maker Perrigo plans to spend about $ 2.1 billion to buy European company HRA Pharma. The purchase is expected to be finalized in the first half of next year, assuming it gets approved by regulators. Based in Paris HRA Pharma manufactures several over-the-counter blister care, women’s health […]]]>

GRAND RAPIDS, Mich. (WOOD) – West Michigan self-care maker Perrigo plans to spend about $ 2.1 billion to buy European company HRA Pharma.

The purchase is expected to be finalized in the first half of next year, assuming it gets approved by regulators.

Based in Paris HRA Pharma manufactures several over-the-counter blister care, women’s health and scar care products, as well as some specialty drugs for rare diseases. Perrigo says its acquisition is expected to “significantly strengthen (its) global footprint.”

“With the addition of HRA and its talented management team, Perrigo would be a global leader in consumer personal care that is poised to deliver leading net sales growth and double-digit growth (earnings per share ) in the short term while simultaneously developing margins, ”Perrigo President and CEO Murray Kessler said in a statement. “… This is literally a unique opportunity to simultaneously improve our financial profile, while creating even greater value for consumers, shareholders and the communities in which we work and live. “

Perrigo says it expects to save $ 30 million in the first year of the acquisition by combining and streamlining its and HRA operations. He added that the purchase of HRA could increase sales by around $ 400 million in fiscal year 2023.

Perrigo, an over-the-counter giant in the United States, currently has its North American headquarters in Allegan, but is working on relocation of HQ to Grand Rapids,

`)); // Integrated Facebook script (function (d, s, id) {var js, fjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = identifier; js.src = “https://connect.facebook.net/en_US/sdk.js#xfbml=1&version=v2.12&appId=166116077300962&autoLogAppEvents=1″; fjs.parentNode.insertBefore (js, fjs); } (document, ‘script’, ‘facebook-jssdk’)); // Integration of the Twitter script (function (d, s, id) {var js, tjs = d.getElementsByTagName (s)[0]; if (d.getElementById (id)) return; js = d.createElement (s); js.id = identifier; js.setAttribute (‘async’, ”); js.src = “https://platform.twitter.com/widgets.js”; tjs.parentNode.insertBefore (js, tjs); } (document, ‘script’, ‘twitter-js’)); } // Simplify some iframe stuff var iframes = $ (‘iframe’); iframes .filter (‘.responsive’) .each (function (_, frame) {// 16×9 responsive ratio iframes var $ frame = $ (frame); $ (frame) .css ({position: ‘absolute’, top: 0, left: 0, right: 0, width: ‘100%’, height: ‘100%’,}). Parent (). AddClass (‘wood-responsive-container wood-responsive-container-16×9’);} ); var lazyFrames = iframes .filter (‘[data-lazy-src]’); function woodMakeLazyFrame (selector) {var observer; var options = {root: null, rootMargin: ‘0px’, threshold: 0,}; function handler (entries, observer) {entries.forEach (function (entry) {var ioR = entry.intersectionRatio; if (ioR> 0) {entry.target.src = entry.target.dataset.lazySrc; observer.unobserve ( entry .target);}}); } observer = new IntersectionObserver (manager, options); observe.observ (selector); } lazyFrames.each ((_, frame) => woodMakeLazyFrame (frame)); }); } (jQuery))


Source link

]]>
https://diazon.net/perrigo-buys-european-drug-company-for-around-2-billion/feed/ 0
Personalized regenerative medicine company developing implanted cell pockets to treat chronic diseases https://diazon.net/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/ https://diazon.net/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/#respond Mon, 09 Aug 2021 07:00:00 +0000 https://diazon.net/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/ Crystal Nyitray, Ph.D., CEO and Co-Founder of Encellin provided an overview of the company’s emerging cellular technology to treat chronic endocrine disorders, hypoglycemia and hypocalcemia. Why did you start this business? Encellin was founded because we have a unique opportunity to help millions of patients. The technology developed at UCSF needed a way forward, so […]]]>

Crystal Nyitray, Ph.D., CEO and Co-Founder of Encellin provided an overview of the company’s emerging cellular technology to treat chronic endocrine disorders, hypoglycemia and hypocalcemia.

Why did you start this business?

Encellin was founded because we have a unique opportunity to help millions of patients. The technology developed at UCSF needed a way forward, so we created Encellin. Starting a business also gives you the opportunity to create a specialized team of people dedicated to advancing therapy. We are creating a culture that cares about helping patients and has the courage to try new ways of thinking.

Nyitray crystal

We recently announced the closure of a $ 5.9 million Seed financing round. The round was co-led by Khosla Ventures and SV Latam Capital, with participation from Sandhill Angels and Y Combinator.

What need are you looking to meet in the field of health?

There are 10,000 billion cells in our body that work to keep us healthy. And when these cells are damaged or missing, patients contract disease. Cellular therapies begin to solve these problems by restoring missing or damaged cell functions. To safely deliver cells to the body, the host must be either:

A) Immune removed so that the foreign tissue can be protected or

B) Dose with an immune-protected cell which leaves the recipient unprotected against continuously growing cell lines.

Encellin has developed a way to protect implanted cells and protect the host from unwanted cells. We protect cells and protect humans. With our technology, we can enable cells to be living drugs in the body that can provide therapy when and where it’s needed.

What does your product do? How it works?

Encellin invented a soft cell encapsulation (CED) device that works like a pocket to contain and help cells survive in the body. Encellin’s CED enables closed cells to function as intelligent molecular factories, releasing therapeutic agents when needed. Our new CED allows cells from different sources to be loaded into the CED and implanted into a recipient. Once implanted, cells within the CED are able to maintain their normal function and exchange necessary biomolecules with the host environment to provide therapeutic benefit.

Is this your first healthcare startup? What is your background in the health field?

Encellin is my first startup, but before Encellin, I helped dozens of companies exit UCSF. I was at Sanofi’s External Science and Partnering, and before that, I was doing my PhD. at UCSF where the core Encellin technology was developed. I want to help patients and structure my career in places where I can advance cutting edge technology.

What is the economic model of your company?

Encellin is building a pipeline of cell therapies focused on important unmet clinical needs with a clear mechanism of action.

Who is your client?

Our ultimate customer is the patient. However, we will also work with hospitals and payers to ensure these products can be properly covered to ensure accessibility for patients.

How to generate income?

Encellin is developing cell therapies and will follow a standard model of therapeutic revenue generation.

Do you have clinical validation for your product?

Encellin is a preclinical stage company with proof of concept in animals. Our main programs are at the doorstep of the clinic entrance.


Source link

]]>
https://diazon.net/personalized-regenerative-medicine-company-developing-implanted-cell-pockets-to-treat-chronic-diseases/feed/ 0
Celularity, Clinical-Stage Cellular Medicine Company, Goes Public Following $ 138 Million Merger https://diazon.net/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/ https://diazon.net/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/#respond Fri, 16 Jul 2021 07:00:00 +0000 https://diazon.net/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/ Common shares of the combined company, Celularity, Inc., will begin trading on the Nasdaq Capital Market under the symbol “CELU” on July 19. Celularity, Inc., a clinical-stage cellular medicine company that develops ready-to-use allogenotherapies derived from the postpartum human placenta, today announced its IPO. The news comes after the finalization of the merger with GX […]]]>

Common shares of the combined company, Celularity, Inc., will begin trading on the Nasdaq Capital Market under the symbol “CELU” on July 19.

Celularity, Inc., a clinical-stage cellular medicine company that develops ready-to-use allogenotherapies derived from the postpartum human placenta, today announced its IPO.

The news comes after the finalization of the merger with GX Acquisition Corp, a specialist acquisition company. The company will operate under the name Celularity, Inc., and effective July 19, the company will begin trading on the Nasdaq Capital Market under the ticker symbol “CELU”.

Proceeds from the transaction totaled approximately $ 138 million, which includes funds held in GXGX’s trust account and a concurrent private placement in the public equity financing led by existing Celularity shareholders. Celularity’s management team will continue to lead the combined company as a result of this transaction.

“Celularity aims to transform the way we approach the treatment of cancer and other diseases by harnessing the versatility, unique immune biology and innate strain of placental-derived cells,” said Robert J. Hariri, MD, Ph. D., Founder, President and CEO of Celularity. “We are extremely proud of our clinical development results to date, as well as the advanced manufacturing capabilities we have built to support rapid scale-up and a competitive cost structure for our cell-derived therapies. of the placenta. We believe that out-of-the-box allogeneic cell therapies will lead to a paradigm shift in the way clinicians approach the treatment of cancer and other serious illnesses.

Hariri added, “Our PIPE is led by existing Celularity investors, who understand the company’s pipeline and clinical development program and have taken the opportunity to add to their investment in Celularity. partnerships with leaders like Palantir and Arthrex which we believe will strengthen our intellectual property and increase revenues from its existing marketed products.

Dean C. Kehler, Co-President and CEO of GX Acquisition Corp. and new Celularity board member, added, “We are delighted to see Celularity take this very important next step in its evolution as a transformative biotech company to become a publicly traded company.

“This step will allow Celularity to continue to leverage the company’s business and clinical assets to treat high unmet need, such as cancer, infectious diseases and degenerative diseases,” he added.

The company’s clinical pipeline includes several clinical stage programs, including acute myeloid leukemia (AML) and glioblastoma multiforme (GBM), with a total of five clinical programs expected by the first half of 2022.

CYNK-001, the Company’s flagship product candidate, is the only cryopreserved, allogeneic, ready-to-use cell therapy to be developed from placental hematopoietic stem cells. The agent expresses perforin and granzyme B, has shown cytotoxic activity against hematologic tumors and solid tumor cell lines, and can secrete immunomodulatory cytokines in the presence of tumor cells.

The new therapy is being explored as a potential option in multiple myeloma, acute myeloid leukemia (AML) and glioblastoma multiforme; it is also evaluated in infectious diseases like COVID-19 (NCT04365101).


Source link

]]>
https://diazon.net/celularity-clinical-stage-cellular-medicine-company-goes-public-following-138-million-merger/feed/ 0
Meet the founders of Genexa, the 1st ‘Clean Medicine Company’ https://diazon.net/meet-the-founders-of-genexa-the-1st-clean-medicine-company/ https://diazon.net/meet-the-founders-of-genexa-the-1st-clean-medicine-company/#respond Tue, 29 Jun 2021 07:00:00 +0000 https://diazon.net/meet-the-founders-of-genexa-the-1st-clean-medicine-company/ Us Weekly has affiliate partnerships, so we may receive compensation for certain links to products and services. For generations, families have searched the drug aisle for products without looking at the ingredients. They took an over-the-counter medicine and never thought about what was inside; the only thing that mattered was that it relieved the condition […]]]>

Us Weekly has affiliate partnerships, so we may receive compensation for certain links to products and services.

For generations, families have searched the drug aisle for products without looking at the ingredients. They took an over-the-counter medicine and never thought about what was inside; the only thing that mattered was that it relieved the condition being treated. Why would they do it? It’s easy to think that trusted pharmaceutical companies would create safe, effective, and healthy products for everyone.

When the founders of Genexa looked around the drug aisle they found something they really weren’t comfortable with: tons of man-made fillers that included common allergens, parabens, and an assortment of synthetic ingredients that they didn’t not wanted in the bodies of their children.

Meet the founders of the first clean medicine company, David Johnson and Max Spielberg. These two dads are on a mission to clean the medication aisle. Johnson and Spielberg realized they weren’t happy with the ingredients in their children’s medications and worked with a team of medical professionals to transform the over-the-counter industry by making clean products.

Genexa products have the same effective active ingredients as conventional over-the-counter drugs – ingredients that offer therapeutic or medicinal value and have undergone years of scientific testing to ensure safety. The difference is in the inactive ingredients.

Because Genexa only uses clean inactive ingredients, families get drugs without artificial additives and common allergens – drugs that won’t have any of the potentially unwanted side effects that can be associated with unnecessary synthetic ingredients in conventional drugs. Genexa is reinventing the way conventional pharmaceutical drugs are made, focusing on delivering the exact same OTC drugs without potentially harmful fillers contained in their inactive ingredients. Genexa does not seek to subvert conventional pharmaceutical medicine; rather, they focus on delivering the exact same OTC drugs without the potentially harmful fillers contained in their inactive ingredients.

Johnson and Spielberg believe that drugs can be effective and clean; people deserve better, and that’s why they created Genexa – real medicine, made clean.

Genexa

Genexa’s medical team has formulated a clean drug line that sets a new standard in the OTC industry

From the start, Johnson and Spielberg sought out experienced healthcare professional partners. These partners now form the Genexa Medical Advisory Board, a team of leading experts who have played a fundamental role in advancing healthcare in their fields. With these healthcare professionals and the expertise of people like Brian Perkins, president of Genexa and former global president of Consumer Pharmaceuticals & Nutritionals at Johnson & Johnson, Genexa has successfully launched clean over-the-counter drugs in many categories including allergies, pain and fever, colds and coughs. and digestion.

They have spent years doing extensive research and development, creating cutting edge technology to remove unnecessary synthetics and potential toxins from their formulas. The medical team has formulated a line of clean drugs that sets a new standard in the OTC industry.

Genexa breathes a breath of fresh air into the OTC industry and ensures that every family has access to the clean medicines they deserve.

These over the counter medications are exactly what you didn’t know you needed.

GMO-free, organic, gluten-free solutions designed to get everyone better

Genexa finally makes it possible to have both effective active ingredients and clean formulas. Genexa drugs are available at major retailers like Target, Walmart, Walgreens, CVS, Kroger, and Whole Foods, as well as at Genexa.com. If you order directly from their site, you will be able to choose from clean medicine cabinet sets so kids and adults can easily refuel.

With active ingredients like acetaminophen and inactive ingredients like organic blueberry flavor and citrus extract, the Pain and fever in children medication from Genexa is a must have at home, with the Cough and congestion in children and the Immune support for children. If you are looking for clean medicines for your child’s symptoms, Genexa has some clean products that you should have in your medicine cabinet.

Genexa is the only clean medicine company that has removed inactive artificial ingredients from its products, such as propylene glycol, sorbitol, wheat starch, stearyl alcohol, sodium benzoate, and disodium EDTA. This means that parents can feel better about what they are giving their children.

With Genexa, people know they are looking for medicines that will help them and their children safely.

You can also create your own personalized cleaning doctor’s office on Genexa.com. With the ability to mix and match clean medications and create a personalized set for the whole family, Genexa gives everyone the ability to bring home exactly what they need.

Genexa makes sure people get the quality products they deserve. Their line includes organic, vegan, gluten-free, and designed medicines to keep everyone improving.

Find the solutions you deserve with Genexa.

Genexa’s mission is to create a more socially and environmentally just world.

Genexa does not stop there. With the launch of their new blog of health resources and guides, their commitment to wellness with impact partners and their sustainable suppliers, they strive to change more than what’s in your business. medicine cabinet.

Genexa is launching a knowledge base that will contain hundreds of resources on common health issues, provide insight into symptoms, causes and treatments, and point people in the right direction when it comes to treating their symptoms.

By partnering with organizations like Thirst Project, Vitamin Angels and March of Dimes, Genexa is also committed to bringing well-being to all. By partnering with Thirst Project, Genexa has helped fund the construction of wells in several locations in El Salvador and brought clean, uncontaminated water to the communities of Lotificación San Alfredo, Cangrejera and La Libertad.

While working with Vitamin Angels and March of Dimes, Genexa has donated to life-saving charities to provide moms and babies with healthy medicine and healthy beginnings.

Genexa’s commitment does not stop there, they are also committed to the planet. Genexa works with companies that are dedicated to sustainable sourcing and has a number of certifications from organizations such as the Sustainable Forestry Initiative and USDA Certified Biobased Product approved renewable packaging. Genexa is also a B certified company and its mission is to create a more socially and environmentally just world.

Genexa is there to help families choose cleanliness.

Genexa
Genexa

There has never been a better time to know exactly what is going on in our body

It’s not every day that a business shows up and opens our eyes to the truth, and with medicine it’s never happened before. Genexa is the only clean drugs company in the OTC industry that shows everyone that they have a different kind of choice, which they see as a healthier choice.

When families realize that Genexa is giving them drugs with the same effective active ingredients and only clean inactive ingredients, there is no other option that makes sense. Genexa is forever changing the drug aisle.

David Johnson and Max Spielberg believe parents around the world deserve the peace of mind that Genexa offers, and that’s because they are parents themselves. No more worries, questions or “What does this ingredient do?” While standing in the medication aisle trying to find a solution as soon as possible.

There has never been a better time to find out exactly what is going on in our body. Clean medicine is calling, it’s time to pick up the phone and go home to our loved ones.

Disclaimer: While we work to ensure that product information is correct, manufacturers may occasionally change their ingredient lists, packaging, products, product images and / or declared results or visuals. We recommend that you always read labels, warnings, and instructions before using or consuming any product. The content on this site is not intended to replace advice given by a physician, pharmacist or other licensed healthcare professional. The information and statements are not intended to diagnose, treat, cure or prevent any disease or health problem. For more information about a product, please contact the manufacturer. Us Weekly assumes no responsibility for any inaccuracies or inaccuracies in the products.

This article is brought to you by the Shop With Us team at Us Weekly. The Shop With Us team aims to highlight products and services that our readers might find interesting and useful, such as face masks, self-tanners, Lululemon style leggings, and all the best gifts for everyone in your life. . The selection of products and services, however, is in no way intended to constitute an endorsement by Us Weekly or any celebrity mentioned in the post.

The Shop With Us team can receive products from manufacturers for free to test. Additionally, Us Weekly receives compensation from the manufacturer of the products we write about when you click a link and then purchase the product featured in an article. It does not determine whether a product or service is featured or recommended. Shop With Us operates independently of the advertising sales team. We appreciate your feedback at ShopWithUs@usmagazine.com. Good shopping!


Source link

]]>
https://diazon.net/meet-the-founders-of-genexa-the-1st-clean-medicine-company/feed/ 0
Precision Medicine Company adyn Raises $ 2.5 Million Seed Funding for Personalized Contraception https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception/ https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception/#respond Mon, 19 Apr 2021 07:00:00 +0000 https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception/ SEATTLE – (COMMERCIAL THREAD) –adyn, a precision medicine company, today announced it has closed a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of […]]]>

SEATTLE – (COMMERCIAL THREAD) –adyn, a precision medicine company, today announced it has closed a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis from Applied Intuition and Ashley Mayer from Glossier.

Side effects are the number one reason women switch to another contraceptive method, with 52% of women trying four or more methods (and that doesn’t even count for multiple types of pills) before finding one that works for them. body. While some side effects, like weight gain and acne, are a nuisance, others, like blood clots and depression, can be life threatening. On average, women in the United States take birth control for 30 years. Today, the standard of care for prescribing hormonal contraceptives is trial and error, and the average time spent on contraceptive counseling is 12.9 minutes. adyn uses proprietary hormonal and genomic analyzes to turn this selection process into a science and take the guesswork out of it. Using adyn’s precision medicine approach, patients and physicians will be able to personalize contraceptive selection, minimizing side effects ranging from annoyances like acne to life-threatening conditions, including blood clots. blood and depression.

Adyn’s flagship product, the Birth Control Optimization Test, is the very first test that uses your biology to personalize your choice of birth control. The home kit collects samples for our lab-developed test that aims to quantify baseline hormone levels and assess the genetic risk for two of the most serious side effects: blood clots and depression. adyn then incorporates this into the medical history and side effect profiles of estrogens and progestins used in hormonal contraception. Adyn-trained birth control specialists share personalized recommendations and are available for ongoing care through adyn’s telemedicine platform.

Adyn’s founder, Dr Elizabeth Ruzzo, received her doctorate in genetics and genomics from Duke University and has spent over 10 years researching and identifying the genetic risk of complex diseases such as epilepsy and autism and has worked to help the field realize its vision of precision medicine. Throughout his academic career, Dr Ruzzo has encountered research gaps that have blocked genetic findings in non-European populations and masked or ignored how biological sex differences contribute to disease and drug response.

Dr Ruzzo said, “The pill has been on the market in the United States since the 1960s, and 64 million women of reproductive age in the United States are fed up with an unscientific, unpredictable contraceptive selection process. and unpleasant. As I was finishing my doctorate in human genomics, I changed my contraceptive prescription and was thrown into suicidal thoughts. Fortunately, I recognized that this was due to the change in medication. The gender gap in medical research and the racial gap in medical research have had profound and devastating impacts on available diagnostics, treatment and care, and adyn seeks to make scientific discovery more inclusive. In order to eliminate trial and error in the selection of birth control, access to your own biological data is essential.

Deena Shakir, Partner of Lux Capital, said: “At the forefront of precision medicine, adyn is finally giving women better options for family planning and more control over their health. Dr Ruzzo and his team have achieved a breakthrough in both technology and business model, which together will fundamentally transform the quality and accuracy of diagnostics and the delivery of healthcare. We are very excited to partner with an incredible Founder, Team and Co-Investors in pursuit of a future where healthcare solutions are as unique as each individual they serve.

M13 partner Christine Choi said: “adyn opens up access to health through personalized scientific information on genetics and hormone levels that are medically exploitable. Dr. Ruzzo’s expertise in precision medicine will introduce a new standard of care for birth control and fill gaps caused by historical inequity in medical research. We are delighted to support cutting edge technology personalized for optimized individual health. ”

Adyn’s waitlist is now open for her birth control optimization test to be shipped this year. To learn more about the product and to join our waitlist rewards program, please visit https://www.adyn.com.

About adyn

adyn is a precision medicine company that makes scientific discovery more inclusive so that everyone can live their healthiest lives. Founded in 2019, adyn provides medically actionable scientific information and empowers individuals to proactively optimize their health, from birth control to fertility and beyond. For more information, follow adyn on Twitter, LinkedIn and Instagram. Please visit https://www.adyn.com.



Source link

]]>
https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception/feed/ 0
Precision Medicine Company adyn Raises $ 2.5 Million Seed Funding for Personalized Contraception https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception-3/ Mon, 19 Apr 2021 07:00:00 +0000 https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception-3/ Gives women personalized contraceptive recommendations to minimize side effects of medications, including blood clots and depression SEATTLE – (COMMERCIAL THREAD) – adyn, a precision medicine company, today announced the closing of a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y […]]]>

Gives women personalized contraceptive recommendations to minimize side effects of medications, including blood clots and depression

SEATTLE – (COMMERCIAL THREAD) – adyn, a precision medicine company, today announced the closing of a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis from Applied Intuition and Ashley Mayer from Glossier.

Side effects are the number one reason women switch to another contraceptive method, with 52% of women trying four or more methods (and that doesn’t even consider multiple types of pills) before finding one that works for them. body. While some side effects, like weight gain and acne, are a nuisance, others, like blood clots and depression, can be life threatening. On average, women in the United States take birth control for 30 years. Today, the standard of care for prescribing hormonal contraceptives is trial and error, and the average time spent on contraceptive counseling is 12.9 minutes. adyn uses proprietary hormonal and genomic analyzes to turn this selection process into a science and take the guesswork out of it. Using adyn’s precision medicine approach, patients and physicians will be able to personalize contraceptive selection, minimizing side effects ranging from annoyances like acne to life-threatening conditions, including blood clots. blood and depression.

Adyn’s flagship product, the Birth Control Optimization Test, is the very first test that uses your biology to personalize your choice of birth control. The home kit collects samples for our lab-developed test that aims to quantify baseline hormone levels and assess the genetic risk for two of the most serious side effects: blood clots and depression. adyn then incorporates this into the medical history and side effect profiles of estrogens and progestins used in hormonal contraception. Adyn-trained birth control specialists share personalized recommendations and are available for ongoing care through adyn’s telemedicine platform.

Adyn’s founder, Dr Elizabeth Ruzzo, received her doctorate in genetics and genomics from Duke University and has spent over 10 years researching and identifying the genetic risk of complex diseases such as epilepsy and autism and has worked to help the field realize its vision of precision medicine. Throughout his academic career, Dr Ruzzo has encountered research gaps that have blocked genetic discovery in non-European populations and masked or ignored how biological sex differences contribute to disease and drug response. .

Dr Ruzzo said, “The pill has been on the market in the United States since the 1960s, and 64 million women of childbearing age in the United States are fed up with a birth control screening process that does not exist. it’s unscientific, unpredictable and unpleasant. As I was finishing my doctorate in human genomics, I changed my contraceptive prescription and was thrown into suicidal thoughts. Fortunately, I recognized that this was due to the change in medication. The gender gap in medical research and the racial gap in medical research have had profound and devastating impacts on the diagnostics, treatment and care available, and adyn seeks to make scientific discovery more inclusive. In order to eliminate trial and error in birth control selection, access to your own biological data is essential.

Deena Shakir, Partner of Lux Capital, said: “At the forefront of precision medicine, adyn is finally giving women better options for family planning and more control over their health. Dr Ruzzo and his team have achieved a breakthrough in both technology and the business model, which together will fundamentally transform the quality and accuracy of diagnostics and the delivery of healthcare. We are very excited to join forces with an incredible Founder, Team and Co-Investors in pursuit of a future where healthcare solutions are as unique as each individual they serve.

M13 partner Christine Choi said: “adyn opens up access to health through personalized scientific information on genetics and hormone levels that are medically exploitable. Dr. Ruzzo’s expertise in precision medicine will introduce a new standard of care for birth control and fill the gaps caused by historical inequity in medical research. We are delighted to support cutting edge technology personalized for optimized individual health. “

Adyn’s waitlist is now open for her birth control optimization test to be shipped this year. To learn more about the product and to join our waitlist rewards program, please visit https://www.adyn.com.

About adyn

adyn is a precision medicine company that makes scientific discovery more inclusive so that everyone can live their healthiest lives. Founded in 2019, adyn provides medically actionable scientific information and empowers individuals to proactively optimize their health, from birth control to fertility and beyond. For more information, follow adyn on Twitter, LinkedIn and Instagram. Please visit https://www.adyn.com.



Source link

]]>
Precision Medicine Company adyn Raises $ 2.5 Million Seed Funding for Personalized Contraception https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception-2/ Mon, 19 Apr 2021 07:00:00 +0000 https://diazon.net/precision-medicine-company-adyn-raises-2-5-million-seed-funding-for-personalized-contraception-2/ Gives women personalized contraceptive recommendations to minimize side effects of medications, including blood clots and depression adyn, a precision medicine company, today announced it has closed a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend […]]]>

Gives women personalized contraceptive recommendations to minimize side effects of medications, including blood clots and depression

adyn, a precision medicine company, today announced it has closed a $ 2.5 million funding round. The cycle was co-led by Lux Capital and M13 with participation from Civilization Ventures, Concrete Rose Capital, Y Combinator, Madrona Pioneer Fund, Ascend VC and angel investors including Anne Wojcicki of 23andMe, Nish Bhat of Color Genomics, Qasar Younis from Applied Intuition and Ashley Mayer from Glossier.

Side effects are the number one reason women switch to another contraceptive method, with 52% of women trying four or more methods (and that doesn’t even consider multiple types of pills) before finding one that works for them. body. While some side effects, like weight gain and acne, are a nuisance, others, like blood clots and depression, can be life threatening. On average, women in the United States take birth control for 30 years. Today, the standard of care for prescribing hormonal contraceptives is trial and error, and the average time spent on contraceptive counseling is 12.9 minutes. adyn uses proprietary hormonal and genomic analyzes to turn this selection process into a science and take the guesswork out of it. Using adyn’s precision medicine approach, patients and physicians will be able to personalize contraceptive selection, minimizing side effects ranging from annoyances like acne to life-threatening conditions, including blood clots. blood and depression.

Adyn’s flagship product, the Birth Control Optimization Test, is the very first test that uses your biology to personalize your choice of birth control. The home kit collects samples for our lab-developed test that aims to quantify baseline hormone levels and assess the genetic risk for two of the most serious side effects: blood clots and depression. adyn then incorporates this into the medical history and side effect profiles of estrogens and progestins used in hormonal contraception. Adyn-trained birth control specialists share personalized recommendations and are available for ongoing care through adyn’s telemedicine platform.

Adyn’s founder, Dr Elizabeth Ruzzo, received her doctorate in genetics and genomics from Duke University and has spent over 10 years researching and identifying the genetic risk of complex diseases such as epilepsy and autism and has worked to help the field realize its vision of precision medicine. Throughout his academic career, Dr Ruzzo has encountered research gaps that have blocked genetic findings in non-European populations and masked or ignored how biological sex differences contribute to disease and drug response.

Dr Ruzzo said, “The pill has been on the market in the United States since the 1960s, and 64 million women of childbearing age in the United States are fed up with a birth control screening process that does not exist. it’s unscientific, unpredictable and unpleasant. While completing my doctorate in human genomics, I changed my contraceptive prescription and was thrown into suicidal thoughts. Fortunately, I recognized that this was due to the change in medication. treatment and care, and adyn seeks to make scientific discovery more inclusive. In order to eliminate trial and error in birth control selection, access to your own biological data is essential. “

Deena Shakir, Partner of Lux Capital, said: “At the forefront of precision medicine, adyn is finally giving women better options for family planning and more control over their health. Dr Ruzzo and his team have achieved a breakthrough in both the technology and the business model. which together will fundamentally transform the quality and accuracy of diagnostics and health care delivery. “

M13 associate Christine Choi said: “adyn opens up access to health through personalized scientific information on genetics and hormone levels that are medically exploitable. Dr. Ruzzo’s expertise in precision medicine will introduce a new standard of care for birth control and fill the gaps caused by inequity in medical research. We are delighted to support cutting edge technology personalized for optimized individual health. “

Adyn’s waitlist is now open for her birth control optimization test to be shipped this year. To learn more about the product and to join our waitlist rewards program, please visit https://www.adyn.com.

About adyn

adyn is a precision medicine company that makes scientific discovery more inclusive so that everyone can live their healthiest lives. Founded in 2019, adyn provides medically actionable scientific information and empowers individuals to proactively optimize their health, from birth control to fertility and beyond. For more information, follow adyn on Twitter, LinkedIn and Instagram. Please visit https://www.adyn.com.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210419005465/en/

Contacts

Media
Emilie Ruzzo
press@adyn.com



Source link

]]>